Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 2 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 2 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides a source of calories and glucose, which is metabolized to carbon dioxide and water, yielding energy. Sodium chloride maintains fluid and electrolyte balance.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion; typical adult maintenance dose is 1-2 L per 24 hours adjusted based on fluid and electrolyte needs. Rate determined by clinical condition.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Dextrose: variable, approximately 1-2 hours for plasma glucose in euglycemic state; sodium and chloride: 6-12 hours depending on renal function and hydration status.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Dextrose and sodium chloride are endogenous substances; excess dextrose is metabolized to CO2 and water, with negligible renal excretion of unchanged glucose; sodium and chloride are primarily excreted renally (over 90% of filtered load).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte